



September 16, 2024

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides receives USFDA approval for Fluoxetine Tabs 60 mg; Expanding the Product’s Availability Across Strengths.”**

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
**Company Secretary**  
**ICSI Membership No. A30515**

Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700  
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

# Strides receives USFDA approval for Fluoxetine Tabs 60 mg; Expanding the Product's Availability Across Strengths

- *Fluoxetine Tabs 60 mg approval solidifies the Company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules*

**Bangalore, India, September 16, 2024** - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Fluoxetine Tabs 60 mg, from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Fluoxetine Tablets, 60 mg, of TWi Pharmaceuticals, Inc.

With the approval of the Fluoxetine Tabs 60 mg strength, the Company is now positioned to offer a complete portfolio of Fluoxetine across Capsules and Tablets in 10 mg, 20 mg, and 60 mg strengths. Fluoxetine Capsules and Tablets have a combined market size of ~US\$ 130 Mn as per IMS.

The addition of the Fluoxetine Tabs 60 mg will allow for enhanced flexibility in dosing, catering to a broader spectrum of patient needs. The Company plans to launch all three strengths in the near future. The Fluoxetine tablets will be manufactured at the company's facility in Puducherry.

## About Fluoxetine

Fluoxetine is an antidepressant of the Selective Serotonin Reuptake Inhibitor (SSRI) class. It is used for the treatment of Major Depressive Disorder (MDD), Obsessive–Compulsive Disorder (OCD), Bulimia Nervosa, Panic Disorder, with or without Agoraphobia.

## About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com).

For further information, please contact:

**Institutional Investors**

**Vikesh Kumar**

Group CFO

[investor-relations@strides.com](mailto:investor-relations@strides.com)

**Saurabh Ambaselkar**

Investor Relations

+91 99609 31220

[saurabh.ambaselkar@strides.com](mailto:saurabh.ambaselkar@strides.com)

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp. Office: Strides House, Bannerghatta Road,  
Bengaluru – 560076

**Corporate Communication**

**Pallavi Panchmatia:** +91 80 6784 0193

[Pallavi.panchmatia@strides.com](mailto:Pallavi.panchmatia@strides.com)

**PR Consultancy**

Adfactors PR

**Janhavi Bellare:** +91 93228 54508

[Janhavi.bellare@adfactorspr.com](mailto:Janhavi.bellare@adfactorspr.com)

**Talal Syed:** +91 99876 19679

[syed.talal@adfactorspr.com](mailto:syed.talal@adfactorspr.com)